Silver Book Fact

TAVR Success in sSAS Patients

A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable, and 1.1% for those at intermediate surgical mortality risk.

Kodali S, Thourani V, White J, et al. Early Clinical and Echocardiographic Outcomes After SAPIEN 3 Transcatheter Aortic Valve Replacement in Inoperable, High-Risk and Intermediate-Risk Patients with Aortic Stenosis. Eur Heart J. 2016; 37: 2252-62. https://academic.oup.com/eurheartj/article/37/28/2252/2237654/Early-clinical-and-echocardiographic-outcomes

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • TAVR improves quality of life in SAS patients
     
  • In 2010, ~67,500 SAVRs were performed in the U.S.
     
  • From approval in 2011 through 2015 >54,000 TAVRs were performed in 418 centers in 48 states
     
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
  • Survival rates of SAS patients ages 80+ with and without SAVR